Literature DB >> 9302781

[Diagnosis of human neurocysticercosis by ELISA-IgG using a purified antigen].

P Salinas1, L Sandoval, E Rugiero, M C Contreras.   

Abstract

An analysis of immunodiagnosis data for human neurocysticercosis (NC) by ELISA-IgG, complement fixation test (CFT) and indirect hemagglutination test (IHAT) in 67 serum samples and 54 cerebrospinal fluids (CSF) from confirmed cases of different hospitals from the Metropolitan Area of Santiago, Chile, was performed. The cut-off value was determined by using serum samples from 60 apparently healthy persons, whose absorbance values were the mean plus three standard deviations. The sensitivity of ELISA was 97.0% and 100% for serum samples and CSF respectively. This assay was considered of statistical significance (p < 0.05) when it was compared with CFT. Specificity was established by testing a purified antigen over 109 different helminthiasis serum samples, 185 neurological affections other than NC and 60 control samples. A 98.3% of global specificity was found. The use of ELISA-IgG and a purified antigen in the approach of immune diagnosis of NC is considered a useful assay, particularly if it is performed on paired serum/CSF samples.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9302781

Source DB:  PubMed          Journal:  Bol Chil Parasitol        ISSN: 0365-9402


  3 in total

1.  Optic nerve cysticercosis: imaging findings.

Authors:  S Chandra; S Vashisht; V Menon; M Berry; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

2.  Accuracy of serological testing for the diagnosis of prevalent neurocysticercosis in outpatients with epilepsy, Eastern Cape Province, South Africa.

Authors:  Humberto Foyaca-Sibat; Linda D Cowan; Hélène Carabin; Irene Targonska; Mushtaq A Anwary; Gilberto Serrano-Ocaña; Rosina C Krecek; A Lee Willingham
Journal:  PLoS Negl Trop Dis       Date:  2009-12-08

Review 3.  Immunological and molecular diagnosis of cysticercosis.

Authors:  Silvia Rodriguez; Patricia Wilkins; Pierre Dorny
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.